Resveratrol Downmodulates Neutrophil Extracellular Trap (NET) Generation by Neutrophils in Patients with Severe COVID-19

• Published in: Antioxidants Vol. 11; no. 9; p. 1690
• Main Authors: de Souza Andrade, Milena M, Leal, Vinicius N. C, Fernandes, Iara G, Gozzi-Silva, Sarah C, Beserra, Danielle R, Oliveira, Emily A, Teixeira, Franciane M. E, Yendo, Tatiana M, Sousa, Maria da Glória T, Teodoro, Walcy R, Oliveira, Luana de M, Alberca, Ricardo W, Aoki, Valéria, Duarte, Alberto J. S, Sato, Maria N
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 29-08-2022; MDPI
• Subjects: Antibodies; antioxidant; Antiviral agents; Coronaviruses; COVID-19; Cytokines; Disease; Flow cytometry; Health aspects; Immunopathogenesis; Infections; Leukocytes (neutrophilic); NETs; Neutrophilia; Neutrophils; Patients; Phenols; Plasma; Resveratrol; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Software; supplement; Viral infections; Brazil; New York; United States > US; Germany
• ISSN: 2076-3921; 2076-3921
• DOI: 10.3390/antiox11091690

The formation of microthrombi in lung autopsies indicates the involvement of NETs in the immunopathogenesis of severe COVID-19. Therefore, supplements inhibiting NET formation, in association with drugs with fewer adverse effects, should be a relevant strategy to attenuate the disease. Resveratrol (RESV) is a natural polyphenol with an important antiviral and antioxidant role. To modulate neutrophils from patients infected with SARS-CoV-2, we evaluated the in vitro effect of RESV on NET formation. Herein, we investigated 190 patients hospitalized with moderate, severe, and critical symptoms at Hospital das Clínicas, Brazil. We observed that neutrophilia in patients with severe COVID-19 infection is composed of neutrophils with activated profile able to release NET spontaneously. Notably, RESV decreased the neutrophil-activated status and the release of free DNA, inhibiting NET formation even under the specific PMA stimulus. At present, there is no evidence of the role of RESV in neutrophils from patients with COVID-19 infection. These findings suggest that adjunctive therapies with RESV may help decrease the inflammation of viral or bacterial infection, improving patient outcomes.